TITAN, a phase 3 study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT)

TITAN, a phase 3 study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT) Meeting Abstract

publication date

January 1, 2019

webpage

Web of Science

published in

ONCOLOGY RESEARCH AND TREATMENT Journal

start page

286

end page

286

volume

42